1. General Office of the State Council. Several Policy Measures to Accelerate the Development of Traditional Chinese Medicine’s Distinctive Features (2021) (in Chinese). http://www.gov.cn/zhengce/content/2021-02/09/content_5586278.htm [国务院办公厅. 关于加快中医药特色发展的若干政策措施(2021)]. http://www.gov.cn/zhengce/content/2021-02/09/content_5586278.htm.
2. National Medical Products Administration. Annual Report on National Adverse Drug Reaction Monitoring (2015) (in Chinese). https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20160713155901987.html [国家药品监督管理局. 国家药品不良反应监测年度报告(2015年)]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20160713155901987.html.
3. Li Q, Li B B, Zheng W K, et al. Clinical surveillance cases of clinical safety in 296200 cases of traditional Chinese medicine injection: A systematic review (in Chinese). Chin J Evid Based Med, 2019, 19: 28–35 [李晴, 李蓓蓓, 郑文科, 等. 基于296200例的中药注射剂临床安全性集中监测研究的系统评价. 中国循证医学杂志, 2019, 19: 28–35].
4. Zheng R, Guan M K, Zhong C M, et al. Investigation and analysis of safety information reporting in Chinese herbal injection instructions (in Chinese). Chin J New Drugs Clin Pharmacol, 2020, 31: 363–367 [郑蕊, 关曼柯, 钟长鸣, 等. 中药注射剂说明书安全性信息报告调查分析. 中药新药与临床药理, 2020, 31: 363–367].
5. Xiao X H, Zhao X, Bai Z F, et al. New outlook on safety of traditional Chinese medicine: Concept and practice (in Chinese). China J Chin Mater Med, 2023, 48: 2557–2564 [肖小河, 赵旭, 柏兆方, 等. 中药新安全观及实践. 中国中医杂志, 2023, 48: 2557–2564].